$RGBP "I am pleased to have Dr. Ma assist us in our cellular and animal studies as we move the NR2F6 small molecule program forward. He is an expert in understanding how the human immune system functions in response to various stimuli, and his participation in the program will accelerate the development of small molecule drugs," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.

https://finance.yahoo.com/news/regen-biopharm...00389.html

$MRNS $SPU $AVXL $TWTR $AMZN $FB